Preparation 01eosinophil suspensions. Percoll dilutions were prepared as described previously, with modifications (10) . Briefly, a stock solution of PercoIl was prepared by adding 1 part HBSS lOx to 9 parts Percoll, The osmolality of this solution was measured with a freezing-point osmometer (The Advanced Micro-Osmometer model 3MO; Advanced Instruments, Needham Heights, MA) and adjusted to 340 ± 1 mosmol/L. The density was measured with a glass 2-mL pyknometer (Ace Glass Incorporated, Vineland, NJ). From this stock solution (density 1.123 g/rnl.), five Percoll solutions with gradually increasing densities (1.080, 1.085, 1.090, 1.095, and 1.100 g/ml.) were prepared by adding calculated amounts of HBSS ix. All densities were verified by measurement with a pyknometer. Manipulations of the solutions were carried out under sterile conditions and the Percoll solutions were checked regularly for bacterial or fungal contamination by microscopic examination and culture.
Discontinuous Percoll gradients were prepared in 15-mL conical plastic tubes (Falcon Plastics, Los Angeles, CA), using a 160 Abbreviations RSV, respiratory syncytial virus PMA, phorbol-12-myristate-l3-acetate PAF, platelet activating factor LTC4, leukotriene C4 HBSS, Hanks' balanced salt solution SOD, superoxide dismutase m.o.i., multiplicity of infection ABSTRACT. To determine the nature of the interaction between viruses and eosinophils, normodense eosinophils were separated from the blood of healthy volunteers and incubated in vitro with respiratory syncytial virus (RSV). peristaltic pump (Peristaltic Pump PI; Phannacia Fine Chemicals, Uppsala, Sweden). Two and one half mL of 1.080 g/ml.
Percoll were underlayered subsequently with 3 mL of 1.085 g/ mL, 3 mL of 1.090 g/ml., 2.5 mL of 1.095 g/ml, and 1.5 mL of 1.100 g/ml, Percell.
Five parts blood were mixed with one part 4.5% dextran and left at room temperature for 45 min to sediment the red cells. Twenty-mL aliquots of the leukocyte rich supernatant were underlayered with 10 mL Ficoll-Hypaque (1.076 g/rnl.) and centrifuged (450 x g, 20 min at room temperature). The cell pellet was collected and washed twice with HBSS Ix without calcium or magnesium and finally resuspended in HBSS Ix with 5% neonatal calf serum . A cell count was performed with an automated counter (Coulter counter S+IV; Coulter Corporation, Hialeah, FL), and the suspension adjusted to 20 x 10 6 cells/rnl., Two mL of this cell suspension were layered on top of each Percoll gradient and centrifuged (600 x g, 20 min at room temperature).
Cells from the three lower interfaces (1.100-1.095 , 1.095-1.090, and 1.090-I.085) were collected and washed twice in HBSS Ix with 0.1% gelatin. Residual red blood cells were lysed by hypotonic shock. The number of cells in each band was determined and a differential cell count was performed on cytocentrifuge slides (Cytospin 2; Shandon, Sewickley, PA) after staining with a modified Wright's stain (Stat Stain, VWR Scientific, Piscataway, NJ).
Normodense eosinophils obtained from the 1.095-1.100 interface were used in subsequent experiments. The cell population was 87.8 ± 2.0% pure (n = 17). Viability of the cells after the separation was always more than 98% as determined by trypan blue exclusion. Contaminating cells were exclusively neutrophils.
Virus preparation. RSV (Long strain) was grown in HEp-2 culture monolayers as described (II). When more than 90% cytopathic effectwas observed (48-72 h), the virus was harvested. The virus was stored at -70°C. HEp-2 cell supernatant was processed in the same way to serve as control. The titer of the virus was 5 X 10 5 to 5 X 10 6 plaque-forming units /rnl., as determined by plaque-forming assay.
Immunofluorescence. Eosinophils were incubated with RSV at an m.o.i, of I in serum-free HBSS for 2 or 24 h at 37"C with 5% CO2• After incubation, the cells were washed, fixed on glass slides, and stained with a FITC-conjugated monoclonal anti-RSV antibody (Bartels Immunodiagnostic Supplies, Sacramento, CA). The slides were then examined under a fluorescence microscope (Olympus Optical Co. Ltd., Shinjuhn-Tokyo, Japan) by two independent investigators.
Superoxide generation . Generation of superoxide was determined as SOD-inhibitable reduction of ferricytochrome c as previously described (12) . The tests were carried out in flatbottom, 96-well microtiter plates (Dynatech Laboratories, Alexandria, VA), and the color change was measured in an automated ELISA reader at 550 nm (Titertek Multiskan Plus MKlI ; Flow Laboratories, McLean, VA). After adding the stimuli to the wells, the plate was read six times in the first 30 min and at 15-min intervals thereafter until the moment a plateau phase in superoxide production was reached. Between readings, the plate was incubated at 37"C with 5% CO 2 • The mean of triplicate wells was calculated and SOD control and spontaneous release were subtracted from the test wells. Superoxide generation was expressed as nmol cytochrome c reduction/S x 10 5 cells per min as described (12) .
Leukotriene production . One million eosinophils were incubated overnight in I mL of RSV-conditioned medium (RPMI 1640 supplemented with 5% FCS) at an m.o.i, of 2 or in an equal amount of control medium, at 37"C and 5% CO 2 • After incubation, the cells were washed twice with HBSS and counted, and the viability was determined by trypan blue exclusion. The cells were subsequently incubated in a total volume of I mL with calcium ionophore A23 I87 at a final concentration of 2.5 ILM for 10 min in a shaking water bath. The reaction was stopped by addition of 1.5 mL of ice-cold methanol. Twenty ng of prostaglandin B 2 were added as an internal standard for HPLC analysis. The resultant mixture was centrifuged at 1000 x g for 15 min at 4°C. The supernatant was applied to a CI8 reversed phase extraction cartridge (Sep-Pack; Millipore, Waters Associates, Milford, MA) that had been washed previously with 10 mL of distilled HPLC-grade water and activated with 10 mL HPLCgrade methanol. After the sample was placed on the cartridge, it was washed with 10 mL of distilled water and the leukotrienes were eluted with 10 mL of70% methanol. The methanol fraction was evaporated under vacuum in a rotary evaporator (Rota vapor, Buchi, Switzerland) and the residue was redissolved in 500 ILL of 30% methanol and stored at -70T until testing. The samples were injected into a C 18 reverse-phase column (Beckman, San Ramon, CA) and eluted isocratically at a flow rate of I mL/min in a HPLC system (Pharmacia, Piscataway, NJ) with a solvent system of methanol/water/acetic acid (70/28/2 vol/vol/vol) adjusted to pH 5.5 with ammonium hydroxide. The eluate was monitored at 280 nm by a wavelength spectrometric detector (Phannacia). For identification and quantification of LTC4 in the samples, different mixtures of purified LTC4 and prostaglandin B 2 were prepared in HBSS and processed as described above. Each sample was tested in parallel with these standards.
Reagents. HBSS with and without calcium and magnesium, RPMI 1640, and neonatal calf serum were purchased from Gibco Laboratories (Grand Island, NY). Gelatin was obtained from Bio-Rad Laboratories (Richmond, CA). Dextran , Percoll, PMA, calcium ionophore A23187, fonnyl-methionyl-Ieucyl-phenylalanine , SOD, horse-heart ferricytochrome c (type VI), prostaglandin B2, and platelet activation factor t -e-pbosphatidylcbolinc. Statistical methods. The t test for paired samples was used to compare group means. All values are expressed as mean ± SEM.
R ESULTS
Association of RSV with eosinophils. Eosinophils were incubated with live RSV and then stained with FITC-conjugated MAb to RSV. After 2 h of incubation, 29.5 ± 15.8% of the eosinophils demonstrated significant staining for viral antigen (n = 4). The staining appeared as bright spots rather diffusely distributed over the eosinophil cell membrane, sometimes confluent to a larger area of immunofluorescence on the cell (Fig.  I) . However, cells incubated with RSV for 24 h revealed no RSV-specific staining in any of the eosinophil preparations studied (n = 3). To exclude the possibility that contaminating neutrophils might show the positive staining, only cell preparations consisting of more than 95% eosinophils were used for the immunofluorescence studies. Cells incubated with virus-free HEp-2 cell supernatant or control culture medium did not show any fluorescence.
Superoxide production. Eosinophil preparations were stimulated with PMA in a final concentration of I or 10 ng/ml, or PAF at a final concentration of 10-6 M to establish a reference curve for eosinophil superoxide production kinetics (12) . As shown in Figure 2 , peak superoxide production was observed after 180 min of incubation with PMA I ng/ml, or PAF 10-6 M. On the other hand, superoxide production by the eosinophils stimulated with PMA 10 ng/ml, reached a peak level at 30 min.
The maximum superoxide production was 38. cells for the low PMA concen trat ion and 11.5 ± 7.5 nmol cytochrome c redu ction/ 5 x 10 5 cells for PAF. Eosinophil s were incubated with live RSV at an m .o.i, of I, and the kinetics of superoxide release was determined over the following 180 min (Fig. 3) . Eosinophils of three volunteers did not demonstrate any reactivity toward RSV, although the superoxid e produ ction by control cells stim ulated with PMA was a ppropriate (data not shown). Eosinoph ils from two volunteers demonstrated a very low bu t consistent superoxi de release after in cubation with the virus (max ima l release 1.05 ± 0. RSV-induced superoxide production by the neutrophils could be detected, although the cells were activated appro priately by PM A and for myl-methionyl-leucyl-phenylalan ine (data not shown). In addition , different perce ntages of neutroph ils (5-15 %) in the cell suspe nsions did not affect th e activation of eosinoph ils (data not shown). The stock RSV preparation did not contai n measurable amo unts of superoxide.
To evaluate if RSV had a priming effect on eosinophils, resulting in a more pronounced pro ductio n of superoxide after subsequent challenge, eosinophils were incubated with the virus at an m .o.i, of 1 for 30 min at 37"C and 5% CO 2 • After two washing steps with HBSS, the cells were plated and challenged with PMA at a con centration of 1 ng/rnl., The data on eosinophil preparations of four different volunteers are presented in Figure  4 . Th e maximal PMA-in du ced superoxide release by cells preincuba ted with RSV was 32.6, 16.5, 7. Eosinophils incubated with HEp-2 cell supernatant did not produce detectable superoxide, nor was a priming effect noted.
Leukotrienerelease. Incubation of 1 x 10 6 pu rified eosinophils from different donors for up to 12 h in the presence of live RSV or HEp-2 cell superna tant did not induce release of any sulfidopeptide leukotrienes. Shorter incubation s (30, 60, or 120 min ) did not result in LTC4 release either (data not shown). However, incubat ion of the eosino phils for 12 h in contro l medium followed by a challenge with a suboptimal concentra tion of calcium ionoph ore A23 187 resulted in the release of detectable amounts ofLTC4 (4.2 ± I.3 ng LTC 4/1 x 10 6 cells). When the eosinophils were preincubated with RSV for 12 h and then challenged with calcium ionophore, significantly higher amounts of LTC4 were released (9.16 ± 1.04 ng LTC4/ 1 x 10 6 cells)( n = 6)(p < 0.005 ) (Fig. 5) . HEp-2 cell-conditio ned medium, however, did not show any priming effect on the eosinoph ils. 
DISCUSSION
The findings of this study suggest that RSV is capable of stimulatory interaction with eosinophils. One third of the cells demonstrated specific fluorescent membrane staining after 2 h of exposure to the virus, This finding contrasts with a previous report in which positive staini ng was not obtained after incubatio n of polymorp honuclear granulocytes with RSV and subseq uent staining of the cells with anti-RSV MAb (13) . However, nonpurified granu locyte suspensions were used in that study, an d the cells were only examined after 24 h. In the present study, RSV-eosinophil interactions reversed spontaneously by 24 h of inc ubation.
Activation of eosinophils of healthy subjects by respiratory syncytial virus described in the present study was evident from t he release of superoxide and LTC4• The magnitude of superoxide prod uction due to RSV stimulation varied among the subjects but was clearly detectable in five of eight individuals (63%) tested. Furthermore, the virus primed the cells to release significantly more superoxide on subsequent challenge with PMA and also sensitized eosinophils to release higher amo unts of LTC. in response to a subsequent challenge with calcium ionophore.
The mechanism and initiati ng steps of the oxidative metabolism of neutro phils is well un derstood. A similar understanding of the respiratory burst of eosinop hils has been inhibited because of technical difficulties in separating cells from peripheral blood and because superoxide assays have required large numbers of cells. In the present study, a recently described microassay for measurement of superoxide production by small numbers of phagocytic cells was used (12, 14, 15) . PMA stimulates eosinophiIs to release toxic oxygen metabolites through a mechanism bypassing the initial receptor-mediated activation and starting the chain of superoxide generation directly at the level of phosphokinase C. PAF stimulates the cells through interaction with specific membrane receptors (16) . The mechanism by which RSV activates the eosinophils to release oxygen radicals is not clear. Nonspecific phagocytosis of the virus by the cells is possible, but the interaction of RSV with a thus far uni dentified putative receptor on the eosinophils cannot be ruled out. The possibility that eosinop hils are indirectly activated by factors released by HEp -2 cells infected with RSV cannot be ruled out complete ly by this study , altho ugh to our knowledge there exists no evidence suggesting HEp -2 cells as a source of cytokines or other factors inducing or media ting stimulation of eosinophils .
The interindividua l variability in superoxide generation cannot be explained at the present time. The dono rs had no sympto ms of atopic disease and did not report other recent illness, nor were they taking any medication that could blunt or accentuate the response. Serum-specific anti-RSV antibody titers as determi ned by ELISA were similar for all the subjects (data not shown), probabl y excluding variability in immune comp lex formation as a mechanism.
RSV did not induce directly a release of LTC. from the eosinophils. However, cells incubated in the presence of the virus exhibited a significantly stronger response when challenged subsequently with calcium ionop hore. The priming of eosinophils by monokines and eosinophil chemotactic factors has been previously described (17, 18) . Ingestion of the viral particles by the cell or interaction of RSV with the eosinophil memb rane may render the cells more active upon stimulation with a chemica l stim ulus such as calcium ionophore.
To date, the only reports describing the activation of gran ulocytes by RSV in vitro involve the interaction ofRSV and neutrophils. Neut roph ils produce superoxide and thromboxane B2 when challenged with RSV (19) , demonstrate a significant chemiluminescence when incubated with RSV-antibody immune complexes (20) , attach to RSV-infected HEp-2 cells (II), and are cytotoxic for RSV-infected targets (21) . The present study provides information on RSV-specific activatio n of purified eosinophils.
The demonstration that RSV can both induce the prod uction . of superoxide and prime the eosinop hils to release higher amo unts of mediators after subsequent challenge leads to the speculation that some of the inflammatory signs seen in the airways of children with RSV bronchiolitis might be eosinophilinduced. Indeed, it has been shown that eosinophil mediators such as major basic protein and products of the respiratory burst can induce damage of respiratory epithelium and airway smooth muscle in vitro (22) (23) (24) (25) (26) . Viral damage to respiratory epithelium could work in concert with toxic damage by eosinophil prod ucts and edema with bronchoconstriction induced by LTC4 to bring about the airway obstruction seen in RSV bronchiolitis.
